Centiva Capital’s Takeda Pharmaceutical TAK Stock Holding History

Centiva Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-18,630	Closed	-$265K	–	2361
2024 Q3	$265K	Buy	+18,630	New	+$264K	0.01%	1653

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Centiva Capital's TAK Position: Q4 2024 in Review

Centiva Capital sold out of Takeda Pharmaceutical (TAK) in Q4 2024, closing a stake of 18,630 shares — an estimated $265K sold.

Centiva Capital first reported a position in TAK in Q3 2024 and held it in 1 quarter. The position peaked at $265K in Q3 2024. 301 funds tracked by Wall St. Rank hold TAK as of Q4 2024.

Centiva Capital reported no remaining Takeda Pharmaceutical position as of Q4 2024 after selling out during the quarter.
Centiva Capital sold 18,630 Takeda Pharmaceutical shares in Q4 2024, an estimated $265K.
Centiva Capital first reported a position in Takeda Pharmaceutical in Q3 2024 and held it in 1 quarter.
Centiva Capital's Takeda Pharmaceutical position peaked at $265K in Q3 2024.
301 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.